Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the invention relates to a pharmaceutical formulation with delayed release of active ingredient, which contains 6-dimethylaminomethyl-1 - (3-methoxyphenyl) cyclohexane-1, 3-diol or one of its pharmaceutically acceptable salts in a matrix.
• 6-Dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1, 3-diol is known from EP 0 753 506 B1 and US 5,733,936 as an analgesic drug and can be administered orally.
• the usual formulations for the oral administration of 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cycIohexane-1, 3-diol lead to a relatively quick release of the active ingredient in the gastrointestinal tract, so that its analgesic effect also begins quickly. At the same time, however, a relatively rapid decline in the effect is observed.
• 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cycIohexane-1, 3-diol lead to a relatively quick release of the active ingredient in the gastrointestinal tract, so that its analgesic effect also begins quickly. At the same time, however, a relatively rapid decline in the effect is observed.
• Dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1, 3-diol has hitherto been administered at relatively short intervals, for example three to four times a day, in order to ensure a sufficient concentration of active substance in the patient's blood plasma.
• a pharmaceutical dosage form with delayed release (sustained release formulation) for oral administration of the active ingredient 6-dimethylaminomethyl-1 - (3-methoxy-phenyl) -cyclohexane-1, 3-diol is therefore desirable.
• slow release formulations for a large number of different active compounds are generally known. Common forms of retardation include coating retardation and matrix retardation.
• the core of a pharmaceutical composition containing an active ingredient is provided with a coating of one or more hydrophilic and / or hydrophobic polymers which delays the release of the active ingredient.
• the active ingredient is contained in a matrix formed from one or more carrier materials, which controls the release of the active ingredient.
• DE 33 09 516 A1 discloses a method for producing matrix formulations
• HPMC Hydroxypropylmethylcellulose
• the carrier material making up no more than a third of the weight of the formulation and consisting of at least one hydroxypropylmethylcellulose which has a methoxy content of 16-24% by weight and a hydroxypropyl content of 4 -32 wt .-% and has a number average molecular weight of at least 50,000.
• the formulations disclosed in DE 33 09 516 A1 contain HPMCs with viscosities (in 2% strength by weight aqueous solution at 20 ° C.) between 15 and 30,000 cPs (15 to 30,000 mPa * s). A release behavior that is independent of the pH of the dissolution medium is not disclosed in DE 33 09 516 A1.
• This object is achieved by a pharmaceutical formulation with delayed release, which contains 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1, 3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed release of active ingredient, the Contains matrix 1 to 80 wt .-%, preferably 5 to 80 wt .-%, of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and has the following release rate in vitro, measured using the Ph.
• Another object of the invention is a pharmaceutical formulation with delayed release, the 6-dimethylaminomethyl-1 - (3-methoxy-phenyl) -cyclohexane-1, 3-diol or a pharmaceutically acceptable salt thereof in a sustained release matrix, the matrix containing 1 to 80% by weight of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and having the following rate of release in vitro as measured using Ph. Eur. Paddle Method at 75 rpm in a buffer (according to Ph.
• the formulations according to the invention release the active ingredient 6-dimethylaminomethyl-1- (3-methoxyphenyl) cyclohexane-1, 3-diol with a delay in oral administration and are therefore free for administration at intervals of at least 12 hours if necessary, also at intervals of at least 24 hours.
• the formulation according to the invention accordingly allows one Pain therapy, in the course of which the analgesic 6-dimethylaminomethyl-1- (3-methoxyphenyl) cyclohexane-1, 3-diol only once a day, for example at intervals of 24 hours, or twice a day, preferably at intervals of 12 hours , must be administered to ensure a sufficient plasma concentration of the active ingredient.
• a corresponding duration of action and the maintenance of sufficient blood plasma levels is proven by simulation studies and experimental investigations.
• Formulation ensures long-term therapeutic efficacy not only because of the delayed release, but also because of the resulting favorable exploitation of the high half-life of the active metabolite that forms, which results in a long-lasting therapeutic effectiveness (at least 12 to 18, possibly 24 hours). Due to this half-life, it is sufficient if the release takes place only over 12 to 18 hours in order to achieve sufficient effectiveness in pain treatment over 24 hours. Thus, this formulation surprisingly lends itself particularly well to taking once a day, something that in comparable others
• Formulations are much more difficult and difficult to achieve.
• the pain patient can thus effectively combat his pain acutely by taking the analgesic in the formulation according to the invention and, at the same time, can effectively treat for a longer period without further measures and only by taking it regularly at intervals of 24 (or 12) hours.
• the active ingredient of the formulation according to the invention is contained in a matrix with delayed release.
• the active substance is contained in a matrix with the usual release behavior and that the delayed release is achieved by a coating retardation.
• the delayed release behavior is achieved by an osmotically driven release system.
• the matrix has 1-80% by weight of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers, for example gums, cellulose ethers, cellulose esters, acrylic resins, derived from proteins Materials, fats, waxes, fatty alcohols or fatty acid esters.
• hydrophilic polymers it is preferred that the matrix has 5 to 80% by weight of matrix formers.
• Another object of the present invention is a pharmaceutical formulation which contains 6-dimethylaminomethyl-1 - (3-methoxyphenyl) cyclohexane-1, 3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed release of active ingredient, the matrix 1 to 80% by weight, in particular 5 to 80% by weight, of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and which is characterized in that it has cellulose ethers and / or cellulose esters as pharmaceutically acceptable matrix formers which / which has / have a viscosity of 3,000 to 150,000 mPa s in a 2% by weight aqueous solution at 20 ° C. (The viscosity is determined using capillary viscometry according to Pharm. Eu.).
• the compositions have the inventive release profile given above.
• cellulose ethers and / or cellulose esters which in a 2% strength by weight aqueous solution at 20 ° C. have a viscosity between 10,000, in particular 50,000 mPa s, and 150,000 mPa s.
• Particularly suitable pharmaceutically acceptable matrix formers are selected from the group of hydroxypropylmethyl celluloses (HPMC), hydroxyethyl celluloses, hydroxypropyl celluloses (HPC), methyl celluloses, ethyl celluloses and carboxymethyl celluloses and are particularly selected from the group of HPMCs, hydroxyethyl celluloses and HPCs.
• HPMCs hydroxypropylmethyl celluloses
• HPCs hydroxyethyl celluloses and HPCs.
• HPMCs with a viscosity of approx. 100,000 mPas, measured in a 2% by weight aqueous solution at 20 ° C.
• the active ingredient 6-dimethylaminomethyl-1 - (3-methoxy-phenyl) -cyclohexane-1, 3-diol can be used as such, i.e. as a free base, but also in the form of a pharmaceutically acceptable salt, for example as hydrochloride.
• a pharmaceutically acceptable salt for example as hydrochloride.
• the preparation of the free base is known from EP 0 753 506 A1 and US 5,733,936.
• pharmaceutically acceptable salts such as hydrochloride
• 6-Dimethylaminomethyl-1 - (3-methoxy-phenyl) -cyclohexane-1, 3-diol has centers of asymmetry so that the compound can be in the form of various stereoisomers.
• 6-dimethylaminomethyl-1 - (3-methoxyphenyl) cyclohexane-1, 3-diol as a mixture of all stereoisomers in any mixing ratio, but also as a mixture of two or three or more stereoisomers in any mixing ratio or in stereoisomerically pure form.
• Stereoisomers are understood to mean, in particular, enantiomers or diastereomers.
• racemic mixture (1 RS, 3RS, 6RS) -6-dimethylaminomethyl-1- (3-methoxyphenyl) cyclohexane-1, 3-diol.
• active ingredient or as possible usable forms of 6-dimethylaminomethyl-1 - (3-methoxy-phenyl) -cyclohexane-1, 3-diol is / are therefore for the purposes of the present invention 6-dimethylaminomethyl-1- (3-methoxyphenyl) cyclohexane-1, 3-diol as a racemic mixture or as a mixture of various of its stereoisomers in any mixing ratio or as one of its pure stereoisomers, each as free base or in the form of a pharmaceutically acceptable salt.
• the active ingredient content to be released with delay is preferably between 0.5 and 85% by weight and the content of pharmaceutically acceptable matrix former is between 8 and 40% by weight.
• the active ingredient content is at the lower limit , ie between 0.5 and 25% by weight (based on the total weight).
• constituents of the matrix of the formulation according to the invention can optionally be digestible long-chain (ie with 8 to 50 C atoms, preferably 12 to 40 C atoms) unsubstituted or substituted hydrocarbons, such as, for example, fatty alcohols, fatty acid glyceryl esters, mineral and vegetable oils and waxes, where Hydrocarbons with a melting point between 25 ° and 90 ° C are preferred.
• fatty alcohols are preferred, very particularly lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol and cetylstearyl alcohol.
• Their content in the matrix is 0 to 60% by weight.
• polyethylene glycols with a content of 0 to 60% by weight can also be contained in the matrix.
• pharmaceutically customary auxiliaries such as fillers, for example lactose, microcrystalline cellulose (MCC) or calcium hydrogenphosphate, and lubricants, lubricants and flow regulators, for example talc, magnesium stearate, can also be used as further constituents.
• Stearic acid and / or highly disperse silicon dioxide may be contained, the total content of which in the tablet is between 0 and 80% by weight, preferably between 5 and 65% by weight.
• the rate of release of an active ingredient from a dosage form depends on the pH of the release medium. During the gastrointestinal passage of the drug, this can fluctuate in a pH range from less than 1 to about 8. These fluctuations can vary from one person to another. Also, with one and the same person from one
• the release profiles of the active ingredient (in the form of the base or one of its pharmaceutically acceptable salts) from a pharmaceutical formulation according to the invention are surprisingly independent of the pH, as can occur physiologically during the gastrointestinal passage.
• Release profiles at an ambient pH of 1, 2, 4.0 and 6.8 are both identical to one another and compared to the release during a pH-time profile of pH 1, 2 above pH 2.3 and pH 6.8 up to pH 7.2.
• a filler is a water-soluble filler, for example lactose, an insoluble filler which does not swell in an aqueous medium, for example calcium hydrogen phosphate. or an insoluble filler which swells in aqueous medium, for example microcrystalline cellulose, is used. All such drugs show a corresponding release behavior.
• the amount of matrix former and the amount of the optional constituents can in each case vary over a relatively wide range, without the therapeutic activity of at least 12 h (or 24 h) at twice (or once) daily application would be questioned (as long as the quantity limits specified above for the active ingredient, matrix former and the other optional components are observed).
• Efficacy for at least 12 hours is e.g. with an active substance content of approx. 32.25% by weight (based on the weight of the total composition) both in a composition of approx.
• HPMC 12.9% by weight HPMC with a viscosity of 100,000 mPa s as matrix former and a content of, for example, MCC as a filler of approximately 52.6% by weight and also in a composition of approximately 25.8% by weight of the same HPMC and approximately 39.7% by weight of MCC (or lactose monohydrate) otherwise the same quantities of lubricants, lubricants and flow regulators are guaranteed.
• MCC or lactose monohydrate
• the formulation according to the invention contains the active ingredient 6-
• the release behavior of the formulation according to the invention is not influenced by the exact amount of the active ingredient, as long as the content limits specified above are observed.
• Pharmaceutically acceptable (or acceptable) salts of the active substance in the sense of this invention are those salts of the active substance which are physiologically tolerable in pharmaceutical use, in particular when used on mammals and / or humans.
• Such pharmaceutically acceptable salts can be formed, for example, with inorganic or organic acids.
• the hydrochloride salt is preferred.
• the pharmaceutical formulations according to the invention can be present both as a simple tablet and as a coated tablet, for example as a film tablet or dragee.
• the tablets are usually round and biconvex; oblong tablet forms are also possible, the one
• granules, spheroids, pellets or microcapsules are also possible, which are filled into sachets or capsules or which can be compressed into disintegrating tablets.
• one or more can be any suitable pharmaceutical ingredient.
• coated tablets one or more can be any suitable pharmaceutical ingredient.
• one or more can be any suitable pharmaceutical ingredient.
• Coating layers are used.
• Known hydroxypropylmethyl celluloses with a low viscosity of approx. 1 to 100 mPa s and a low molecular weight of ⁇ 10,000 are suitable as coating material (for example Pharmacoat 606 with a viscosity of 6 mPa s in a 2% by weight aqueous solution at 20 ° C.) which only slightly influence the release profile of the pharmaceuticals according to the invention.
• Diffusion coatings known to the person skilled in the art, for example based on Swellable but water-insoluble poly (meth) acrylates lead to a modulation of the delay in the release of active ingredient from pharmaceutical formulations according to the invention.
• the active ingredient-containing tablet core which releases the active ingredient with a delayed release, with an active ingredient content preferably between 0.5 and 85% by weight, particularly preferably between 3 and 70% by weight and very particularly preferably between 8 and 66% by weight, can contain an additional active ingredient , which is not released as an initial dose, can be encased by various methods known to the person skilled in the art, for example, dragging, spraying on from solutions or suspensions or by powder application methods, without this contributing to rapid pain relief for the desired delayed release with simultaneous flooding of the active ingredient first administration of the pharmaceutical formulation according to the invention is absolutely necessary.
• Multilayer and coated tablets can contain one or more active ingredient-free coatings.
• the active ingredient can be contained in a customary matrix of microcrystalline cellulose and possibly other pharmaceutical adjuvants, such as binders, fillers, lubricants, lubricants and flow regulators, which are coated or coated with a material which inhibits the delayed release control the active ingredient in an aqueous medium.
• Suitable coating agents are, for example, water-insoluble waxes and polymers, such as polymethacrylates (Eudragit or the like) or water-insoluble celluloses, in particular ethyl cellulose. If necessary, water-soluble polymers, such as polyvinylpyrrolidone, can also be water-soluble in the coating material
• Celluloses such as hydroxypropylmethyl cellulose or hydroxypropyl cellulose, other water-soluble agents such as Polysorbate 80, or hydrophilic pore formers such as polyethylene glycol, lactose or mannitol can be included.
• an osmotically driven release system can also be used to achieve a delayed release.
• At least one, preferably all, surface (s) of the release system preferably that which is / could or could be in contact with the release medium, is semipermeable, preferably provided with a semipermeable coating, so that the surface (s) is permeable to the release medium, but is / are essentially, preferably completely, impermeable to the active substance, the surface (s) and / or optionally the coating having / have at least one opening for releasing the active substance.
• the active ingredient 6-dimethylaminomethyl-1 - (3-methoxyphenyl) cyclohexane-1, 3-dioI or a pharmaceutically acceptable salt thereof preferably (1 RS, 3RS, 6RS) -6-dimethylaminomethyl-1- (3-methoxy -phenyl) -cyclohexane-1, 3-diol or a pharmaceutical acceptable salt of this can - but need not - be present in a matrix.
• This is preferably to be understood as a system in tablet form with a delivery opening, an osmotic drug core, a semipermeable membrane and a polymeric part which exerts pressure.
• OROS® system from ALZA Corporation, USA, whose website or other product information contains details about the OROS® system.
• these are also the OROS® Push-Pull TM system, the OROS® Delayed Push-Pull TM system, the OROS® Multi-Layer Push-Pull TM system, the OROS® Push-Stick System, and also in certain questions the L-OROS TM.
• Embodiments and examples of the specific manufacture of osmotically driven release systems can be found in US Pat. Nos. 4,765,989, 4,783,337 and 4,612,008, which form part of the description of this invention.
• a parenteral implant This means any form of non-biodegradable implant that slowly releases active ingredient over a longer period of time.
• DUROS SYSTEM from ALZA, as described for example in WO 00/54745 and which consists of an inert tube, a semi-permeable membrane, an "osmotic engine", a stamp, a dispensing opening and a depot for receiving the dispensed (Usually highly concentrated) active ingredient solution
• Suitable examples are described in the patents US4612008, US4765989, US4783337, US5264446, US4519801, US4612008, US4783337 and US5082668
• Another example is based on non-biodegradable polymers based on ethylene-vinyl acetate copolymers, such as it is described for example for contraceptives by De Nijs et al (US4,957,119, US5,088,505)
• Another possibility of delayed release is a multipore tablet. Examples of this are the
• transdermal application system Another possibility of delayed release is a transdermal application system. This is understood to mean systems that - if necessary using penetration aids such as
• Plasticizers and penetration accelerators - are applied to the skin and release the active ingredient through the skin into the body. Examples that can all be used here include described in DE 10033853, US 5,411,740, EP 767659, AT185694E, DE 69326848T2. Further examples transferred directly in the formulation are the suitable plasters from EP 0 430 019 B1, WO 98/36728 or WO96 / 19975.
• a parenteral depot system especially in depot systems based on slowly disintegrating or biodegradable polymers.
• examples are polylactide polymers or polyglycolide polymers or in particular polylactide / polyglycolide copolymers (PLGA).
• PLGA polylactide / polyglycolide copolymers
• Examples well known to those skilled in the art of manufacture are manufactured by Alkermes or Medisorb, and in particular for Takeda enantones and trenantones. This term also includes the sprayable gels, especially those that solidify in situ and slowly those in them Release the dissolved active ingredient.
• Atrigel technology and other systems from Atrix (US5,278,201, US5,739,176, US6,143,314), in which PLGA polymers and active ingredients are mixed with pharmaceutically acceptable solvents which, after being introduced into the body, form an implant solidify, and the SABER technology from DURECT, which uses a three to four component system with sucrose acteate isobutyrate (SAIB), a pharmaceutically acceptable solvent such as ethanol and one or more additives, and of course the active ingredient.
• SABER technology from DURECT, which uses a three to four component system with sucrose acteate isobutyrate (SAIB), a pharmaceutically acceptable solvent such as ethanol and one or more additives, and of course the active ingredient.
• SABER technology from DURECT, which uses a three to four component system with sucrose acteate isobutyrate (SAIB), a pharmaceutically acceptable solvent such as ethanol and one or more additives, and of course the active ingredient.
• SAIB sucrose acteate iso
• Another object of the invention is a tablet for the twice daily oral administration of 6-dimethylaminomethyl-1- (3-methoxyphenyl) cyclohexane-1, 3-diol, containing a pharmaceutical formulation according to the invention.
• compositions according to the invention can be prepared, for example, by the following general process: the constituents of the composition (active ingredient, matrix former and optional constituents) are weighed in in order and then sieved on a conventional screening machine.
• the Quadro Comil U10 screening machine can be used, whereby a common screen size is approximately 0.813 mm.
• the screening is then mixed in a container mixer, for example in a Bohle container mixer; Typical working conditions are: Duration approx.
• the powder mixture obtained is then compressed into a tablet on a tablet press.
• a Korsch EKO tablet press can be used with a rounded round punch with a 10 mm diameter.
• the powder mixture can be compacted and then sieved (Comill 3 mm friction chip sieve and then 1.2 mm round perforated sieve) of the compacts, the resulting granules then being added to an EKO tablet press, for example, with the addition of lubricant (e.g. magnesium stearate) 10 mm round stamp is pressed.
• lubricant e.g. magnesium stearate
• the granulation can also be carried out by wet granulation based on aqueous or organic solvents; aqueous solvents with or without suitable binders are preferred.
• the manufacturing process can be readily adapted to the particular requirements and the desired form of administration according to procedures well known in the art.
• the preparation of pharmaceutical formulations according to the invention is characterized by a high reproducibility of the release properties of the compositions obtained, which contain 6-dimethylaminomethyl-1- (3-methoxyphenyl) cyclohexane-1, 3-diol or one of its pharmaceutically acceptable salts.
• the release profile of pharmaceuticals according to the invention proves to be stable.
• Hydroxypropylmethylcellulose (Metolose 90 SH 100,000 from Shinetsu), 80 mg 100,000 mPa s
• Microcrystalline cellulose (Avicel PH 101 from FA. FMC) 61 mg
• Comil U10 sieved using a sieve size of 0.813 mm, mixed in a container mixer (Bohle LM 40) for 15 min ⁇ 15 s at a speed of 20 ⁇ 1 U / min and on a Korsch EKO eccentric press to tablets with a diameter of 10 mm , a radius of curvature of 8 mm and an average tablet weight of 350 mg.
• Example 2 Matrix tablets with the following composition per tablet

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pain & Pain Management (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Rheumatology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Engineering & Computer Science (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34088810

Family Applications (1)

Country Status (6)

Families Citing this family (15)

Family Cites Families (6)

• 2003
  • 2003-07-24 DE DE10333835A patent/DE10333835A1/de not_active Ceased
• 2004
  • 2004-07-20 EP EP04741158A patent/EP1648420A2/de not_active Withdrawn
  • 2004-07-20 CA CA002533330A patent/CA2533330A1/en not_active Abandoned
  • 2004-07-20 WO PCT/EP2004/008081 patent/WO2005009329A2/de active Application Filing
  • 2004-07-20 JP JP2006520768A patent/JP2006528604A/ja active Pending
• 2006
  • 2006-01-19 US US11/334,344 patent/US20060121113A1/en not_active Abandoned
• 2010
  • 2010-04-09 US US12/757,455 patent/US20100196473A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events